Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Moderate Buy” from Brokerages

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has received a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $20.20.

Several equities analysts have recently commented on BCYC shares. Citizens Jmp upped their price target on shares of Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a research report on Friday, October 31st. Citigroup reaffirmed an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st. Royal Bank Of Canada reissued a “sector perform” rating and issued a $11.00 price objective (down from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. JMP Securities set a $12.00 target price on Bicycle Therapeutics in a research note on Friday, October 31st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Monday, December 22nd.

Bicycle Therapeutics Trading Down 3.7%

NASDAQ:BCYC opened at $6.95 on Tuesday. The stock has a 50 day moving average of $6.89 and a 200-day moving average of $7.37. The firm has a market capitalization of $482.12 million, a PE ratio of -1.92 and a beta of 1.52. Bicycle Therapeutics has a 52 week low of $6.03 and a 52 week high of $13.63.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.24. The business had revenue of $11.73 million during the quarter, compared to analyst estimates of $8.25 million. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%. As a group, analysts predict that Bicycle Therapeutics will post -3.06 EPS for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 10,989 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $6.46, for a total value of $70,988.94. Following the completion of the sale, the chief executive officer directly owned 618,996 shares in the company, valued at $3,998,714.16. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Alethia Young sold 4,334 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the transaction, the chief financial officer directly owned 87,081 shares of the company’s stock, valued at approximately $565,155.69. The trade was a 4.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 38,029 shares of company stock worth $251,966 over the last 90 days. 22.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Assetmark Inc. raised its position in Bicycle Therapeutics by 74.9% in the third quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after acquiring an additional 1,552 shares in the last quarter. Ausdal Financial Partners Inc. acquired a new position in shares of Bicycle Therapeutics in the 2nd quarter worth approximately $70,000. Sei Investments Co. acquired a new stake in Bicycle Therapeutics during the second quarter valued at approximately $74,000. Virtus Investment Advisers LLC boosted its holdings in Bicycle Therapeutics by 32.6% during the second quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock worth $75,000 after buying an additional 2,659 shares in the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in Bicycle Therapeutics in the second quarter worth approximately $86,000. Institutional investors own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.